Eli Lilly recently updated Q4 revenue guidance, and sales are expected to come in lower than previously anticipated. While this could suggest the company is experiencing sluggish or plateauing ...

In the first half of 2024, it seemed Eli Lilly (NYSE: LLY) could do no wrong. Unfortunately, the good times didn't last very long. The stock peaked last October and was down by more than 21% when ...

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...

2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE: LLY). At one point, share prices had gained as much as 65% on the year. However, after a less-than-spectacular earnings ...

Youngkin said "the pain and sorrow this clemency causes the ... "I’m outraged by Biden granting clemency to cop killers, forcing the fallen officer’s child, Crissana, to relive this trauma.

A SINGLE mum's suspected diabetes symptoms turned out to be incurable cancer. Jodie Hill, 46, was told she had three months to live just before her son Alfie's 13th birthday. It all started when ...

Eli Lilly unexpectedly lowered its full-year 2024 guidance. The miss appears to stem from a lack of the typical December scripts boost. The stock is attractively valued at current levels.

She previously was Baltimore’s health commissioner. Hypertension is frequently referred to as the “silent killer” because it can cause significant lasting damage before people experience ...

Eli Lilly can’t seem to recover from its GLP-1 stumble. Once again, the drugmaker reported sales of its blockbuster GLP-1 medicines Zepbound and Mounjaro that missed Wall Street estimates.